AI
RPRX icon

Atria Investments’s Royalty Pharma RPRX Stock Holding History

Atria Investments’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$736K Buy
15,341
+1,212
+9% +$53.1K 0.01% 1235
2025
Q4 		$546K Buy
14,129
+2,362
+20% +$90.1K 0.01% 1388
2025
Q3 		$415K Buy
11,767
+3,530
+43% +$128K ﹤0.01% 1526
2025
Q2 		$297K Sell
8,237
-1,065
-11% -$35.3K ﹤0.01% 1720
2025
Q1 		$290K Sell
9,302
-13,331
-59% -$423K ﹤0.01% 1636
2024
Q4 		$577K Sell
22,633
-20,550
-48% -$545K 0.01% 1252
2024
Q3 		$1.22M Sell
43,183
-7,639
-15% -$212K 0.02% 876
2024
Q2 		$1.34M Buy
50,822
+11,803
+30% +$327K 0.02% 801
2024
Q1 		$1.19M Buy
+39,019
New +$1.15M 0.02% 881

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Atria Investments's RPRX Position: Q1 2026 in Review

Atria Investments increased its Royalty Pharma (RPRX) stake by 8.6% in Q1 2026, buying an estimated $53.1K and bringing the position to 15,341 shares worth $736K. The position accounts for 0.01% of the portfolio, ranked #1235.

Atria Investments first reported a position in RPRX in Q1 2024 and has held it in 9 quarters since. The position peaked at $1.34M in Q2 2024. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Atria Investments held 15,341 shares of Royalty Pharma worth $736K as of Q1 2026.
  • Atria Investments bought 1,212 Royalty Pharma shares in Q1 2026, an estimated $53.1K.
  • Royalty Pharma made up 0.01% of Atria Investments's portfolio in Q1 2026, its #1235 holding.
  • Atria Investments first reported a position in Royalty Pharma in Q1 2024 and has held it in 9 quarters since.
  • Atria Investments's Royalty Pharma position peaked at $1.34M in Q2 2024.
  • 587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Atria Investments's 13F filing for Q1 2026, filed 5 May 2026.